Search results
Added:
2 months ago
Source:
Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte…
View more
Cardiovascular Disease and Type 2 Diabetes
Added:
1 year ago
Review Article
Separated Vasoreactivity Testing of ACH
Added:
1 year ago
Expert Opinion
Added:
1 year ago
A new policy statement released by HRS underscores the importance of continual training and education for electrophysiologists performing catheter ablation of atrial fibrillation (AF).In this short interview, Dr Kenneth Ellenbogen (VCU School of Medicine, US) discusses the key recommendations within this policy statement to ensure a strong electrophysiology base and skillset to achieve the best…
View more
Added:
1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the…
View more
Added:
1 year ago
ECO 2024 — Prof Sven Francque (University of Antwerp, BE) joins us to talk about the new EASL-EASD-EASO Practice Guidelines for MAFLD.In this interview, Prof Francque highlights some of the unmet needs in people with MAFLD (formerly known as NAFLD). He then summarises the key highlights of the latest guidelines, including guidance on treatment options. He also discusses some of the challenges…
View more
Added:
1 year ago
ESC Congress 2024 — Dr Dipak Kotecha (University of Birmingham, UK) joins us onsite in London to discuss key highlights from the ESC Atrial Fibrillation 2024 guidelines.Interview Questions:1. What is the prevalence of AF and the unmet needs of patients in 2024?2. What's new in the guidelines?3. What are some areas for improvement?4. What are some of the challenges and opportunities with the…
View more
Added:
1 year ago
ESC Congress 2024 — Chair, Prof Isabelle C Van Gelder (University of Groningen, NL) joins us to discuss key highlights from the ESC Atrial Fibrillation 2024 guidelines.The new guidelines centre on shared and equal care, patient empowerment, comorbidities and risk factor management, and evidence-based management and re-evaluation. The new AF-CARE pathway integrates comorbidity management,…
View more
Added:
1 year ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,…
View more
Added:
1 year ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to…
View more